The purpose of this observational case series is to assess the use of Corplex P as a resorbable particulate device used to cover, protect, and provide a moist wound environment when added to the standard of care treatment of hard-to-heal wounds.
This is a retrospective, single-center observational case series to assess real-world outcomes of StimLabs dehydrated human umbilical cord particulate used in the management of hard-to-heal wounds, including acute and chronic ulcers. This case series will include real-world data from up to 10 subjects at one participating site. The Corplex P product has been utilized in a variety of patients attending wound clinics for management of partial and full-thickness wounds, pressure ulcers, venous leg ulcers (VLU), diabetic foot ulcers (DFUs), chronic vascular ulcers, and surgical wounds. The device is intended to cover, protect, and provide a moist wound environment. Medical records will be reviewed for subjects who received the Corplex P product, and data will be collected from baseline, first presentation, treatment, and follow up data. Data summaries will review wound closure, percent are reduction in wound size over treatment time, number of device applications required during treatment, time to wound closure, and adverse events.
Study Type
OBSERVATIONAL
Enrollment
10
Corplex P is derived from human birth tissue and used in wound management to cover, protect, and provide a moist wound environment.
Family Foot & Ankle Specialists, LLC
Bridgeport, Connecticut, United States
The proportion of target ulcers achieving complete wound closure during the observational period
Determine the percent (%) of target ulcers achieving complete wound closure at 12 weeks.
Time frame: 1-12 weeks
Percent area reduction
Percent Area Reduction (PAR) will be calculated from Treatment Visit 1 to Treatment Visit 12.
Time frame: 1-12 weeks
Time to closure for the target ulcer
Time to closure (days) will be determined from the first device application to the date when the wound is first documented as fully closed.
Time frame: 1-12 weeks
Adverse Events
Incidence of adverse events will be evaluated during each treatment visit
Time frame: 1-12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.